elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q42329441-9F9D5A93-64FF-428E-8037-D885C31C3398
Q42329441-9F9D5A93-64FF-428E-8037-D885C31C3398
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42329441-9F9D5A93-64FF-428E-8037-D885C31C3398
Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST® T1).
P2860
Q42329441-9F9D5A93-64FF-428E-8037-D885C31C3398
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42329441-9F9D5A93-64FF-428E-8037-D885C31C3398
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
f31b73e8475d413afba982ea1c8975533f586d47
P2860
Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical